Klinička studija
CLINICAL STUDY HAS CONFIRMED THAT INOFEM® THERAPY (2 SACHETS PER DAY FOR 3 MONTHS) INFLUENCES SIGNIFICANTY ON REDUCTION OF SYMPTOMS WHICH ARE ASSOCIATED TO POLYCYSTIC OVARY SYNDROME (PCOS).
REGULATION OF THE MENSTRUAL CYCLE
81% OF PATIENTS HAVE EXPERIENCED A SPONTANEOUS OVULATION.
INSULIN RESISTANCE
IN 41% OF PATIENTS INSULIN RESISTANCE HAS DECREASED.
LOWERING THE RATIO OF LH TO FSH
IN 19% OF PATIENTS LH/FSH RATIO HAS DECREASED.
IMPROVEMENT OF CARDIOVASCULAR PARAMETERS
Women with PCOS are characterized by increased risk of cardiovascular diseases: hypertension, coronary artery disease, myocardial infarction. The reduction of mean arterial pressure (MAP) and heart rate reduces the risk of cardiovascular diseases especially in patients with PCOS in menopausal and perimenopausal period.
